GlassScriptPhysician profile
Satinder S Purewal
NPI 1528161908
$6,192.77
in general payments reported to CMS, 2019-2025
27 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,533 · 2020: $1,036 · 2021: $2,089 · 2022: $660 · 2023: $305 · 2024: $411 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,048.63 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $555.63 | 2019-2023 | Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $504.01 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $492.78 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $410.78 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $361.79 | 2019-2024 | Spravato, Invega Trinza, Invega Sustenna |
| Allergan, INC. | $348.57 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $346.74 | 2019-2025 | |
| Alkermes, INC. | $326.94 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $301.99 | 2019-2022 | |
| Eisai INC. | $232.14 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $206.03 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $145.12 | 2019-2021 | |
| Lundbeck LLC | $142.41 | 2019-2024 | Rexulti |
| Bausch Health US, LLC | $138.10 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $119.89 | 2019-2025 | Sublocade, Perseris |
| Merck Sharp & Dohme LLC | $111.88 | 2021-2022 | |
| Neuronetics, INC. | $99.51 | 2019 | |
| Neos Therapeutics, LP | $56.40 | 2019 | |
| Shire North American Group INC | $54.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $50.05 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $38.32 | 2022-2023 | Loreev Xr |
| Jazz Pharmaceuticals INC. | $26.29 | 2019-2020 | |
| Orexo US, INC. | $24.58 | 2025 | Zubsolv |
| Bioxcel Therapeutics, INC. | $19.88 | 2023 | Igalmi |
| Ironshore Pharmaceuticals INC. | $15.64 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satinder Purewal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.